David Ghez

David Ghez

Auto-generated profile, based on publicly available information

David Ghez

Clinical Hematology Department Gustave Roussy Villejuif France

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
LHLayal El Halabi
Layal El Halabi
JAJulien Adam
Julien Adam
PGPauline Gravelle
Pauline Gravelle
VMVirginie Marty
Virginie Marty
ADAlina Danu
Alina Danu
DGDavid Ghez
David Ghez

21 June 2017 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
JLJulien Lazarovici
Julien Lazarovici
MTMarie Terroir
Marie Terroir
JAJulia Arfi-Rouche
Julia Arfi-Rouche
Jean Marie MichotJean Marie Michot
Jean Marie Michot
SMSacha Mussot
Sacha Mussot
DGDavid Ghez
David Ghez

2 April 2021 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
KLKamel LARIBI
Kamel LARIBI
MSMohamad Sobh
Mohamad Sobh
DGDavid Ghez
David Ghez
AMAlix Baugier de Materre
Alix Baugier de Materre

31 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Jean Marie MichotJean Marie Michot
Jean Marie Michot
SMSeverine Mouraud
Severine Mouraud
JAJulien Adam
Julien Adam
JLJulien Lazarovici
Julien Lazarovici
CBCamille Bigenwald
Camille Bigenwald
Vincent RibragVincent Ribrag
Vincent Ribrag
Background: Resistance to anti-PD-1 remains a considerable clinical challenge for the treatment of patients with classical Hodgkin lymphoma (cHL), and mechanisms of anti-PD-1 resistance remain unknown. This pilot study aims to investigate the tumor microenvironment in patients with cHL relapsing after anti-PD-1. Methods: This study investigated tumor samples of eight patients with cHL, including four patients exposed to anti-PD-1 with a paired longitudinal histological analysis before and after anti-PD-1, and four patients not exposed to anti-PD-1 who served as control for the cellular biological investigations. Fresh cells tumor microenvironment analysis included phenotypic characterization of their T cell surfaces immune checkpoint markers PD-1, PD-L1, ICOS, TIM-3, LAG-3, 41-BB and BTLA. Tumor tissues immunohistochemistry staining included CD30, CD4, CD8, CD68, CD163, PD-L1, PD-1, LAG-3 and TIM-3. Findings: Paired longitudinal tumor tissues analysis in the tumor microenvironment found a CD8+ lymphocytes tumor depletion and an increase of LAG-3 staining after anti-PD-1 exposure. The fresh cells analysis of the tumor microenvironment in patients exposed to anti-PD-1 found CD8+ lymphocyte depletion, with an elevated CD4+/CD8+ lymphocytes ratio (median ratio 9.77 in exposed anti-PD-1 versus 2.39 in not-exposed anti-PD-1 patients; p = 0.0943). On the cell surfaces of CD4+ lymphocytes, the median positive expression of LAG-3 was significantly higher in the samples exposed to anti-PD-1 compared to the controls (15.05 [IQR:17.91–10.65] versus 3.84 [IQR 1.87–6.57]; p = 0.0376). Interpretation: This pilot study proposes hypotheses for understanding the resistance to immunotherapies in patients with Hodgkin lymphoma. Hodgkin lymphoma exposed to anti-PD-1 correlated in tumor microenvironment with an immune depletion of CD8+ T lymphocytes and overexpression of LAG-3 on CD4+ helper T lymphocytes.

13 February 2025 in Blood Advances
Verified
Journal Article
Open access
SKSabine Khalife-Hachem
Sabine Khalife-Hachem
APArnaud Pagès
Arnaud Pagès
EAElie Akoury
Elie Akoury
SBSarah Bonnet
Sarah Bonnet
RBRudy Birsen
Rudy Birsen
DGDavid Ghez
David Ghez

1 August 2002 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
DGDavid Ghez
David Ghez
PWPierre-François Westeel
Pierre-François Westeel
IHIsabelle Henry
Isabelle Henry
APAndré Pruna
André Pruna
AFAlbert Fournier
Albert Fournier
KLKaiss Lassoued
Kaiss Lassoued